CorpDev.Org
Daily News for Dealmakers
Big Deal
Bob Iger Just Got the Better of Sam Altman: Disney’s Strategic Win in AI Content Licensing
In a landmark move that underscores Disney’s strategic acumen under CEO Bob Iger, The Walt Disney Company has secured a pivotal licensing and investment deal with OpenAI, led by CEO Sam Altman. This agreement not only positions Disney as the...
Home Depot’s $5.5 Billion GMS Acquisition: Strategic Masterstroke in Pro Market Expansion
Home Depot's acquisition of GMS Inc. for $5.5 billion represents a transformative consolidation in the building products distribution sector, accelerating its penetration into the professional contractor market through subsidiary SRS Distribution....
Metro Bank’s Majority Shareholder Explores Stake Sale Amid Private Equity Interest
Colombian billionaire Jaime Gilinski Bacal, Metro Bank's controlling shareholder with a 52.87% stake, is actively exploring a sale of his position following unsolicited investor interest and a sustained share price recovery. This development comes...
Shell Denies BP Mega-Merger: Strategic Implications for the Energy Sector
Shell's swift denial of merger talks with BP marks a pivotal moment in energy sector consolidation, revealing deeper strategic realignments as oil giants navigate volatile markets. The proposed $80 billion acquisition would have created a $300...
Record M&A Insurance Payouts Signal Fundamental Shift in Transaction Risk Management
Aon's landmark Global Transaction Solutions Claims Study reveals unprecedented activity in representations and warranties (R&W) insurance, with North American clients recovering a record $300 million in paid claims during 2024 alone—the highest...
Explainers
Thought Leadership
Private Equity
Technology, Media and Telecom
International
International
Tech, Media & Telecom
Financial Services
Health & Life Sciences
Japanese Pharmas Expand Cross-Border M&A Footprint in US and EU Amid Domestic Market Stagnation
Japanese pharmaceutical companies are increasingly pursuing mergers and acquisitions (M&A) beyond their domestic borders, targeting strategic assets in the United States and Europe to drive growth and innovation. This shift reflects a broader...
Teleflex Divests Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion
Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, announced a strategic divestiture of its Acute Care, Interventional Urology, and Original Equipment Manufacturing (OEM) businesses for a combined cash consideration of...
Mirum Pharmaceuticals Expands Rare Liver Disease Portfolio with $820 Million Bluejay Therapeutics Acquisition
Mirum Pharmaceuticals (Nasdaq: MIRM), a leading rare disease biopharma, announced a definitive agreement to acquire Bluejay Therapeutics, a privately held biotech focused on viral and liver diseases, in a transaction valued at up to $820 million in...
Biocon’s Strategic Integration of Biocon Biologics: A $5.5 Billion Transformation Reshaping Global Biopharmaceutical Leadership
Biotechnology major Biocon has announced a strategic corporate action to fully integrate Biocon Biologics Limited (BBL) as a wholly owned subsidiary into Biocon Limited, valuing the biologics unit at USD 5.5 billion through a combination of share...
AbbVie’s $1.2 Billion Psychedelic Bet Signals Strategic Shift as Retail Investors Weigh Post-Humira Growth
AbbVie's recent acquisition of Gilgamesh Pharmaceuticals' psychedelic depression treatment for up to $1.2 billion represents a pivotal moment in the pharmaceutical giant's post-Humira transformation, yet retail investors remain cautiously...
